Mizolastine provides effective symptom relief in patients suffering from perennial allergic rhinitis: a double-blind, placebo-controlled study versus loratadine
Authors:
- Francisque LeynadierFLFrancisque Leynadier
- 1 September 2002
- journal article
- clinical trial
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 89 (3) , 304-310
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Lack of behavioural toxicity of mizolastine: a review of the clinical pharmacology studiesClinical & Experimental Allergy, 1999
- Changing prevalence of allergic rhinitis and asthmaAnnals of Allergy, Asthma & Immunology, 1999
- Second-Generation AntihistaminesDrugs, 1999
- Comparative Tolerability of Second Generation AntihistaminesDrug Safety, 1999
- Diagnosis and Management of Rhinitis: Complete Guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and ImmunologyAnnals of Allergy, Asthma & Immunology, 1998
- Side effects of rhinitis medicationsJournal of Allergy and Clinical Immunology, 1998
- MizolastineBioDrugs, 1998
- Pathophysiology of perennial allergic rhinitisAllergy, 1997
- Inhibition of Histamine‐Induced Skin Wheal and Flare after 5 days of MizolastineThe Journal of Clinical Pharmacology, 1996
- Late Phase Eustachian Tube and Nasal Allergic Responses Associated with Inflammatory Mediator ElaborationAmerican Journal of Rhinology, 1988